Daunomycin-Related Cardiomyopathy in Children and Adolescents with Improved Acute Lymphoblastic Leukemia and its Relationship with Cardiac Troponin-T Levels

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Pediatrics, Child Health Promotion Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Pediatrics, Child Health Promotion Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Pediatrics, School of Medicine And Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: This study was done to determine the frequency of cardiomyopathy related to Daunomycin in children and adolescents with improved acute lymphoblastic leukemia and its relationship with cardiac troponin-T and cumulative dose of drug.Methods: This cross sectional study was conducted on children and adolescents under age 18 years with improved acute lymphocytic leukemia disease (ALL) and a history of receiving daunomycin who referred to Al-zahra hospital, Iran. People with inclusion criteria based on cumulative dose of daunomycin were divided into two groups. First group of patients were those who received cumulative daunomycin dose fewer than 250 mg/m2 and second group with cumulative dose equal to or greater than 250 mg/m2. In all patients after obtaining consent and taking history, blood levels of cardiac-troponin-T and Shortening Fraction (FS) and Ejection Fraction (EF) indices was measured. Collected data was analyzed by SPSS.Findings: Among 55 patients treated with daunomycin, three patients were diagnosed with cardiomyopathy, all of which were in the second group (P < 0.048). The mean EF in the first group and second group were respectively 65.03+4.26 and 61.4+6.56 (P < 0.02). The mean SF in the first and second group were respectively 34.23+4.19 and 31.92+4 (P < 0.04). Cardiac troponin-T test result was positive in 4 patients from the second group but in the first group there were no positive tests (P < 0.037). There was no significant relationship between cardiomyopathy and increased level of cardiac troponin-T (P = 0.21).Conclusion: Acute lymphocytic leukemia patients treated with daunomycin were at risk for cardiac complications. It is recommended to avoid therapy with a dose more than 250 mg/m2. Since there was not any correlation between cardiac troponin-T level and cardiomyopathy, cardiac troponin-T can not be a reliable marker of delayed cardiotoxicity. 

Keywords

References

  1. Kliegman R, Behrman RE, Nelson WE, Jenson HB, Stanton BF. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders; 2007. p. 2116.
  2. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104(9): 2690-6.
  3. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006; 33(3 Suppl 8): S8-14.
  4. Rathe M, Carlsen NL, Oxhoj H. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48(7): 663-7.
  5. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13(6): 819-29.
  6. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332(26): 1738-43.
  7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-79.
  8. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125(1): 47-58.
  9. Moss AJ, Allen HD. Moss and Adams' heart disease in infants, children, and adolescents: including the fetus and young adult. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.p. 207-19.
  10. Bristow MR,Mason JW,Billingham ME,Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102(4): 709-18.
  11. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004; 91(1): 37-44.
  12. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89(5 Pt 1): 942-9.
  13. Floyd J, Morgan JP, Perry MC. Cardiotoxicity of anthracycline-like chemotherapy agents: Guide-lines for monitoring and drug discontinuation from expert groups[Online]. 2011 May [cited 2010 Nov 3]; Available from: URL: http://www.uptodate.com/contents/cardiotoxicity-of-anthracycline-like-chemotherapy-agents.
  14. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007; 25(24): 3635-43.
  15. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17(7): 2237-43.
  16. Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005; 145(4): 212-20.
Journal of Isfahan Medical School
Volume 29, Issue 145 - Serial Number 145
May and June 2011
Pages 840-846

Files

History

  • Receive Date: 15 June 2011
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics